T
Tetsuya Urasaki
Researcher at Japanese Foundation for Cancer Research
Publications - 38
Citations - 182
Tetsuya Urasaki is an academic researcher from Japanese Foundation for Cancer Research. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 24 publications receiving 55 citations.
Papers
More filters
Journal ArticleDOI
Precision medicine in breast cancer
Yoichi Naito,Tetsuya Urasaki +1 more
TL;DR: This review focuses on precision medicine, especially, genome medicine, in breast cancer, and some of the molecular targeted agents investigated extensively have been investigated extensively.
Journal ArticleDOI
Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis.
Kenji Nakano,Masatoshi Nishizawa,Naoki Fukuda,Tetsuya Urasaki,Xiaofei Wang,Hiroki Mitani,Shunji Takahashi +6 more
TL;DR: A head and neck cancer patient who suffered from corticosteroid-resistant hepatitis during treatment with nivolumab, an anti-PD-1 ICI, and that was recovered by mycophenolate mofetil salvage therapy is treated.
Journal ArticleDOI
Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial.
Yasuyoshi Sato,Naoki Fukuda,Xiaofei Wang,Tetsuya Urasaki,Akihiro Ohmoto,Kenji Nakano,Mayu Yunokawa,Makiko Ono,Yukiko Sato,Hiroki Mitani,Junichi Tomomatsu,Shunji Takahashi +11 more
TL;DR: No significant difference in response rates or survival outcomes was detected between nivolumab-treated HNC patients with primary sites and histological subtypes that were included versus excluded in the CheckMate-141 trial.
Journal ArticleDOI
Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib
Naoki Fukuda,Xiaofei Wang,Akihiro Ohmoto,Tetsuya Urasaki,Yasuyoshi Sato,Kenji Nakano,Masatoshi Nishizawa,Mayu Yunokawa,Makiko Ono,Junichi Tomomatsu,Shunji Takahashi +10 more
TL;DR: Neutrophil-to-lymphocyte ratio values vary before and during lenvatinib treatment, suggesting that this ratio can reflect disease activity of RR-DTC.
Journal ArticleDOI
Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
Akihiro Ohmoto,Yukiko Sato,Reimi Asaka,Naoki Fukuda,Xiaofei Wang,Tetsuya Urasaki,Naomi Hayashi,Yasuyoshi Sato,Kenji Nakano,Mayu Yunokawa,Makiko Ono,Junichi Tomomatsu,Takashi Toshiyasu,Hiroki Mitani,Kengo Takeuchi,Seiichi Mori,Shunji Takahashi +16 more
TL;DR: In this article, the authors conducted a retrospective analysis of 27 patients with poorly differentiated head and neck neuroendocrine carcinoma (NEC) seen at the same institution over a period of 15 years and found that the most common tumor locations were the paranasal sinus (33%) and the oropharynx (19%).